CASP3 and in situ carcinoma: Due to that the treatment with PTX or its combination with CIS increased caspase-3 activation, we evaluated the cleavage of PARP-1 in SiHaP and SiHaCIS-R cells treated with PTX, CIS, or PTX + CIS.